TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06041867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza vaccine
Description: Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaricus bisporus capsules
Description: Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control capsules
Description: Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
Study: NCT05528354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN and DEC based conditioning regimen
Description: Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC
Description: In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed.
Study: NCT04932122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DWG/PIN
Description: Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
Study: NCT04703686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000mg - prephase - one infusion at D-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7082859
Description: 2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
Study: NCT06791616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Surveillance colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Surveillance colonoscopy
Study: NCT06792617

Intervention type: OTHER
Group type: OTHER
Intervention: Mobility (Central or Femoral Cannulation)
Description: Functional Mobility \& ADL's~1. Assisted sitting with progression to unassisted; ADL's~2. Assisted standing with progression to unassisted; ADL's~   1. VitalGo bed will be used if unsafe/unable to perform assisted standing.~  2. Leg press (VitalGo bed)~3. Ambulation; ADL's

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Training
Description: Repetitions will be counted and documented per session per structured exercise.
Study: NCT06791018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be asked to use a cancer-specific exercise mobile app for 12 weeks. The program is designed to achieve the goal of exercising for at least 90 minutes per week, including aerobic exercise three times a week and resistance training twice a week. While exercise equipment is not required, the app supports the optional use of an elastic resistance band or a pair of dumbbells. The app comes with various features to support the exercise journey. Participants will be able to track their progress through periodic testing, access a library of resources that includes information on exercise, and log any additional workouts they perform outside the app. The exercise prescription will be tailored to daily fatigue levels that will be rated before each workout. This ensures that the program is customized to meet individual needs and abilities.
Study: NCT06791213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Multimedia Health Education
Description: This study aims to investigate the effectiveness of digital multimedia in reducing pain, enhancing medication adherence, and improving pain control satisfaction among patients. The goal is to overcome the limitations of busy healthcare providers, allowing patients to learn independently, understand pain and analgesic use, dispel myths about pain medications, and enhance pain control, ultimately improving self-care capabilities, pain control satisfaction, and quality of life.
Study: NCT06792175

Intervention type: DIAGNOSTIC_TEST
Intervention: Solicue Machine Learning Models
Description: A comprehensive machine-learning tool aimed at providing probability estimates for several compatible disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Bipolar Affective Disorder (BPAD), Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia Spectrum Disorders (SSD). By offering a multi-diagnostic assessment based on speech analysis, Solicue aims to assist clinicians in navigating this complexity and potentially identifying conditions that might otherwise be overlooked in initial assessments.~Solicue leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features.

Intervention type: DIAGNOSTIC_TEST
Intervention: Solicue Machine Learning Models
Description: A comprehensive machine-learning tool aimed at providing probability estimates for several compatible disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Bipolar Affective Disorder (BPAD), Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia Spectrum Disorders (SSD). By offering a multi-diagnostic assessment based on speech analysis, Solicue aims to assist clinicians in navigating this complexity and potentially identifying conditions that might otherwise be overlooked in initial assessments.~Solicue leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mercuria Machine Learning Models
Description: Mercuria is designed to stratify the risk of bipolar disorder in individuals presenting with depressive symptoms. This is a critical clinical need, as misdiagnosis of bipolar disorder as unipolar depression is common and can lead to inappropriate treatment, potentially worsening outcomes. By analyzing speech patterns characteristic of bipolar disorder, Mercuria aims to provide an additional tool for clinicians to differentiate between these conditions more accurately, guiding appropriate treatment decisions.~Mercuria leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features.
Study: NCT06790875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Description: In this arm, participants will receive airway pressure release ventilation (APRV), a form of pressure-controlled mechanical ventilation. The high pressure (Phigh) is set based on the plateau pressure of the LTV mode, with a low pressure (Plow) set at 0 cmH₂O. The high pressure time (Thigh) will be set to 4-6 seconds to maintain alveolar recruitment, while the low pressure time (Tlow) will be set to 0.2-0.6 seconds to optimize expiratory flow. This arm aims to evaluate the effects of APRV on lung tissue mechanics, oxygenation, and overall respiratory function in ARDS patients.
Study: NCT05330936

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Potent topical steroid
Description: Cyanocobalamin in Avocado Oil Cream

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Potent topical steroid
Description: Cyanocobalamin in Avocado Oil Cream
Study: NCT06790537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Description: 75 mg of pregabalin will be given at night for the intervention group along with emollient local application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo capsule will be identical in appearance to the pregabalin capsule. it will be given at the same time of the day like pregabalin. same Emollient which is used in the Intervention arm will be applied locally on the areas of itching, morning after bathing .
Study: NCT06778174

Intervention type: OTHER
Intervention: observational study
Description: The interventions are not determined by the study, which is purely observational on real world data.

Intervention type: OTHER
Intervention: observational study
Description: The interventions are not determined by the study, which is purely observational on real world data.
Study: NCT06778798

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization and oral gabapentin
Description: Manual therapy maneuver performed in the upper limb combined with gabapentin oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300mg
Description: Gabapentin oral capsules
Study: NCT06778759

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: median nerve neural mobilization combined with oral ibuprofen arginine
Description: Manual therapy maneuver performed in the upper limb combined with ibuprofen arginine oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Ibuprofen arginine oral tablets
Study: NCT04736199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Coated tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated tablet matching Darolutamide in appearance, oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05213338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear-documentation microchip
Description: Microchip embedded in the appliance
Study: NCT06314789

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: doing lung ultrasonography
Description: In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
Study: NCT05875792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EvolvRehab - MoveWell
Description: The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
Study: NCT04938323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: .1 mL of reconstituted BCG vaccine given intradermally at baseline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: .1 mL of diluent (saline) given intradermally at baseline
Study: NCT05933980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rego+Tori+Cele
Description: combination of Toripalimab,regorafenib and celecoxib
Study: NCT05445674

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Plasma Exchange Procedure
Description: Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Plasma Exchange Procedure
Description: For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
Study: NCT05410483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Hyperthermic Intraperitoneal Docetaxel
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT04736199

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
Study: NCT04770753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching Mitapivat
Description: Tablets
Study: NCT04905485

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VIOME Precision Nutrition Program
Description: Precision diet and supplement recommendations based on participants' microbiome results.
Study: NCT06324669

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone supplement
Description: 100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo with stevia and bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
Study: NCT04861389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial access
Description: Arterial access for primary percutaneous coronary intervention in STEMI patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial access
Description: Arterial access for primary percutaneous coronary intervention in STEMI patients
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05618327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS203 for Injection
Description: 2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter.
Study: NCT05367401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Solution for intravenous infusion
Study: NCT04770753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat
Description: Tablets
Study: NCT05810051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training.
Study: NCT05367401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Solution for subcutaneous injection or intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Solution for subcutaneous injection or intravenous infusion
Study: NCT05638568

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LS test
Description: If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)
Study: NCT04464577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified Dose on Specified Days